FI104539B - Menetelmä muunnellun Neisseria meningitidis ryhmä B polysakkaridin tai muunnellun E. coli K1 kotelomaisen polysakkaridin valmistamiseksi - Google Patents

Menetelmä muunnellun Neisseria meningitidis ryhmä B polysakkaridin tai muunnellun E. coli K1 kotelomaisen polysakkaridin valmistamiseksi Download PDF

Info

Publication number
FI104539B
FI104539B FI922737A FI922737A FI104539B FI 104539 B FI104539 B FI 104539B FI 922737 A FI922737 A FI 922737A FI 922737 A FI922737 A FI 922737A FI 104539 B FI104539 B FI 104539B
Authority
FI
Finland
Prior art keywords
gbmp
polysaccharide
group
butanoyl
protein
Prior art date
Application number
FI922737A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI922737A0 (fi
Inventor
Harold J Jennings
Francis Michon
Original Assignee
Ca Nat Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ca Nat Research Council filed Critical Ca Nat Research Council
Publication of FI922737A0 publication Critical patent/FI922737A0/fi
Application granted granted Critical
Publication of FI104539B publication Critical patent/FI104539B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
FI922737A 1989-12-14 1992-06-12 Menetelmä muunnellun Neisseria meningitidis ryhmä B polysakkaridin tai muunnellun E. coli K1 kotelomaisen polysakkaridin valmistamiseksi FI104539B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44819589A 1989-12-14 1989-12-14
US44819589 1989-12-14
PCT/CA1990/000437 WO1991008772A1 (en) 1989-12-14 1990-12-13 Improved meningococcal polysaccharide conjugate vaccine
CA9000437 1990-12-13

Publications (2)

Publication Number Publication Date
FI922737A0 FI922737A0 (fi) 1992-06-12
FI104539B true FI104539B (fi) 2000-02-29

Family

ID=23779371

Family Applications (2)

Application Number Title Priority Date Filing Date
FI922737A FI104539B (fi) 1989-12-14 1992-06-12 Menetelmä muunnellun Neisseria meningitidis ryhmä B polysakkaridin tai muunnellun E. coli K1 kotelomaisen polysakkaridin valmistamiseksi
FI19991917A FI19991917A7 (fi) 1989-12-14 1999-09-09 Parannettu meningokokki-polysakkaridikonjugaattirokote

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI19991917A FI19991917A7 (fi) 1989-12-14 1999-09-09 Parannettu meningokokki-polysakkaridikonjugaattirokote

Country Status (30)

Country Link
US (3) US5576002A (cg-RX-API-DMAC10.html)
EP (1) EP0504202B1 (cg-RX-API-DMAC10.html)
JP (1) JP2637845B2 (cg-RX-API-DMAC10.html)
KR (1) KR0158436B1 (cg-RX-API-DMAC10.html)
CN (4) CN1049223C (cg-RX-API-DMAC10.html)
AR (1) AR243934A1 (cg-RX-API-DMAC10.html)
AT (1) ATE121947T1 (cg-RX-API-DMAC10.html)
AU (1) AU641715B2 (cg-RX-API-DMAC10.html)
BR (1) BR9007917A (cg-RX-API-DMAC10.html)
CA (1) CA2071811C (cg-RX-API-DMAC10.html)
CZ (1) CZ283530B6 (cg-RX-API-DMAC10.html)
DE (1) DE69019164T2 (cg-RX-API-DMAC10.html)
DK (1) DK0504202T3 (cg-RX-API-DMAC10.html)
ES (1) ES2071288T3 (cg-RX-API-DMAC10.html)
FI (2) FI104539B (cg-RX-API-DMAC10.html)
HR (1) HRP920872A2 (cg-RX-API-DMAC10.html)
HU (2) HU9201966D0 (cg-RX-API-DMAC10.html)
IE (1) IE68414B1 (cg-RX-API-DMAC10.html)
IL (1) IL96676A (cg-RX-API-DMAC10.html)
IN (1) IN171747B (cg-RX-API-DMAC10.html)
NO (2) NO305275B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ236471A (cg-RX-API-DMAC10.html)
PH (1) PH30305A (cg-RX-API-DMAC10.html)
PL (2) PL166659B1 (cg-RX-API-DMAC10.html)
RO (1) RO111416B1 (cg-RX-API-DMAC10.html)
RU (1) RU2105568C1 (cg-RX-API-DMAC10.html)
SI (1) SI20008B (cg-RX-API-DMAC10.html)
WO (1) WO1991008772A1 (cg-RX-API-DMAC10.html)
YU (1) YU24391A (cg-RX-API-DMAC10.html)
ZA (1) ZA9010065B (cg-RX-API-DMAC10.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648241A (en) * 1989-09-15 1997-07-15 The General Hospital Corporation Conjugate vaccine against group B streptococcus
EP0504202B1 (en) * 1989-12-14 1995-05-03 National Research Council Of Canada Improved meningococcal polysaccharide conjugate vaccine
EP0667787B1 (en) * 1992-09-24 2001-07-18 Brigham And Women's Hospital Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5700787A (en) * 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5679654A (en) * 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5747287A (en) * 1995-04-28 1998-05-05 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
HUP9802199A3 (en) * 1995-06-07 1999-07-28 Smithkline Beecham Biolog Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein and use of
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
ZA97248B (en) * 1996-01-18 1997-07-18 Rohm & Haas Method for identifying and quantifying polymers utilizing immunoassay techniques
WO1998008874A1 (en) 1996-08-27 1998-03-05 Chiron Corporation Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions
ES2166097T5 (es) 1996-08-27 2007-03-16 Novartis Vaccines And Diagnostics, Inc. Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos.
US6426074B1 (en) 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
US6413520B1 (en) 1997-06-24 2002-07-02 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
ES2319939T3 (es) 1997-08-27 2009-05-14 Novartis Vaccines And Diagnostics, Inc. Mimeticos moleculares de epitopos de meningococos b.
AU754256C (en) 1997-12-23 2004-05-20 Pfizer Ireland Pharmaceuticals Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugate vaccines
KR100704826B1 (ko) * 1998-08-19 2007-04-09 박스터 헬쓰케어 에스.에이. Ｎ-아크릴로일화된 폴리사카라이드를 사용하여 제조된백신으로서 사용하기에 적합한 면역원성β-프로피온아미도-결합 폴리사카라이드 단백질 컨쥬게이트
RU2249463C2 (ru) * 1998-08-19 2005-04-10 Бакстер Хелфкэа С.А. Иммуногенный конъюгат бета-пропионамид-связанного полисахарида с белком, использующийся в качестве вакцины
US6436653B1 (en) 1998-12-15 2002-08-20 Exiqon A/S Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
US6518037B2 (en) * 1999-11-12 2003-02-11 University Of Iowa Research Foundation Two-component system that controls bacterial membrane synthesis
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
GB0011108D0 (en) * 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
DE60235155D1 (de) * 2001-04-17 2010-03-11 Childrens Hosp Oak Res Inst Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
ES2616180T3 (es) * 2002-03-26 2017-06-09 Glaxosmithkline Biologicals Sa Sacáridos modificados con estabilidad mejorada en agua para su uso como medicamento
BR0310042A (pt) * 2002-05-14 2005-04-05 Chiron Srl Vacinas de combinação mucosal para meningite bacteriana
RU2317106C2 (ru) * 2002-08-02 2008-02-20 ГлаксоСмитКлайн Байолоджикалз с.а. Нейссериальные вакцинные композиции, содержащие комбинацию антигенов
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
CA2520865A1 (en) * 2003-03-31 2004-10-21 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
WO2005016949A2 (en) * 2003-08-12 2005-02-24 Lipoxen Technologies Limited Sialic acid derivatives
AU2005258301A1 (en) * 2004-06-23 2006-01-05 Children's Hospital & Research Center At Oakland Polysaccharide derivatives and uses in induction of an immune response
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
PE20070163A1 (es) 2005-06-27 2007-03-01 Glaxosmithkline Biolog Sa Composicion inmunogenica de conjugados de sacaridos de n. meningitidis
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
GB0611914D0 (en) 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
EP1872791A1 (en) 2006-06-30 2008-01-02 Institut Pasteur Use of bacterial polysaccharides for biofilm inhibition
WO2008157590A1 (en) * 2007-06-20 2008-12-24 Baxter International Inc. Modified polysaccharides for conjugate vaccines
US8815253B2 (en) 2007-12-07 2014-08-26 Novartis Ag Compositions for inducing immune responses
US9050283B2 (en) 2009-01-16 2015-06-09 University Of Maryland, Baltimore Broad spectrum vaccine against non-typhoidal Salmonella
WO2013009945A1 (en) 2011-07-12 2013-01-17 The Brigham And Women's Hospital, Inc. Lipid-containing psa compositions, methods of isolation and methods of use thereof
EP2752403A1 (de) * 2013-01-08 2014-07-09 Sika Technology AG Amin für emissionsarme Epoxidharz-Produkte
CN113637040A (zh) 2015-08-19 2021-11-12 哈佛学院院长及董事 脂化psa组合物和方法
WO2018014012A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
US10183070B2 (en) * 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) * 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4644059A (en) * 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
EP0504202B1 (en) * 1989-12-14 1995-05-03 National Research Council Of Canada Improved meningococcal polysaccharide conjugate vaccine

Also Published As

Publication number Publication date
CN1096516A (zh) 1994-12-21
CN1049223C (zh) 2000-02-09
CZ283530B6 (cs) 1998-04-15
JP2637845B2 (ja) 1997-08-06
US5683699A (en) 1997-11-04
IL96676A (en) 1996-09-12
IE904513A1 (en) 1991-06-19
PL166035B1 (pl) 1995-03-31
AU6898791A (en) 1991-07-18
PL166659B1 (pl) 1995-06-30
HU218146B (hu) 2000-06-28
AU641715B2 (en) 1993-09-30
PH30305A (en) 1997-02-20
DE69019164T2 (de) 1995-09-07
CZ628490A3 (en) 1997-12-17
CN1072506C (zh) 2001-10-10
NZ236471A (en) 1992-10-28
EP0504202B1 (en) 1995-05-03
FI922737A0 (fi) 1992-06-12
IN171747B (cg-RX-API-DMAC10.html) 1992-12-26
US5576002A (en) 1996-11-19
FI19991917L (fi) 1999-09-09
ATE121947T1 (de) 1995-05-15
FI19991917A7 (fi) 1999-09-09
PL288271A1 (en) 1991-12-16
HRP920872A2 (en) 1997-06-30
DE69019164D1 (de) 1995-06-08
CN1055541A (zh) 1991-10-23
WO1991008772A1 (en) 1991-06-27
US5902586A (en) 1999-05-11
ES2071288T3 (es) 1995-06-16
JPH05505392A (ja) 1993-08-12
IE68414B1 (en) 1996-06-12
NO973311D0 (no) 1997-07-17
SI20008B (en) 2001-02-28
NO922316D0 (no) 1992-06-12
NO973311L (no) 1992-08-14
AR243934A1 (es) 1993-09-30
NO305275B1 (no) 1999-05-03
CA2071811C (en) 2003-11-04
ZA9010065B (en) 1992-02-26
CA2071811A1 (en) 1991-06-15
RU2105568C1 (ru) 1998-02-27
SI20008A (sl) 2000-02-29
DK0504202T3 (da) 1995-10-02
IL96676A0 (en) 1991-09-16
NO307835B1 (no) 2000-06-05
CN1100428A (zh) 1995-03-22
EP0504202A1 (en) 1992-09-23
HU9201966D0 (en) 1992-10-28
CN1036522C (zh) 1997-11-26
KR0158436B1 (ko) 1998-12-01
CN1100656A (zh) 1995-03-29
NO922316L (no) 1992-08-14
CN1036504C (zh) 1997-11-26
HUT64480A (en) 1994-01-28
RO111416B1 (ro) 1996-10-31
YU24391A (sh) 1995-12-04
BR9007917A (pt) 1992-10-20

Similar Documents

Publication Publication Date Title
FI104539B (fi) Menetelmä muunnellun Neisseria meningitidis ryhmä B polysakkaridin tai muunnellun E. coli K1 kotelomaisen polysakkaridin valmistamiseksi
JP4656728B2 (ja) ブドウ球菌抗原及びワクチン
US6756361B1 (en) Enterococcus antigens and vaccines
AU706053B2 (en) Modified meningococcal polysaccharide conjugate vaccines